Back to BAX Stock Lookup
Pages: 1 2 »» Last Page

Baxter (BAX) – Press Releases

Aug 14, 2015 09:00 AM Baxter and Water Street Announce FDA Approval of CEFAZOLIN 2 Gram Premix
Aug 6, 2015 04:01 PM Baxalta Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital
Aug 5, 2015 03:17 PM Baxter Comments on Schedule 13D Filing by Third Point
Aug 4, 2015 03:47 PM Baxalta Confirms Receipt of Highly Conditional, Unsolicited Proposal from Shire
Aug 4, 2015 07:30 AM Shire Proposes Combination With Baxalta to Create the Leading Global Biotech Company Focused on Rare Diseases
Aug 3, 2015 09:00 AM Blood Publishes Phase III Data on Baxalta’s Investigational Treatment for Von Willebrand Disease, the Most Common Type of Inherited Bleeding Disorder
Aug 3, 2015 08:30 AM Baxalta Announces Expanded CMS Coverage for Medicare PI Patients to Receive At-Home Treatment with HYQVIA
Jul 30, 2015 07:00 AM Baxalta Reports Positive Sales Momentum in Second Quarter of 2015, Raises Financial Guidance for Second Half of 2015
Jul 29, 2015 04:10 PM Baxter Declares Quarterly Dividend
Jul 29, 2015 04:05 PM Baxter Reports Strong Second Quarter Financial Results Exceeding Guidance
Jul 28, 2015 04:06 PM Baxalta Board of Directors Declares Inaugural Dividend; Approves $1 Billion Share Repurchase Authorization
Jul 27, 2015 08:30 AM Baxalta’s OBIZUR for Acquired Hemophilia A Receives Positive Opinion from European Committee for Medicinal Products for Human Use (CHMP)
Jul 23, 2015 08:30 AM Baxalta Completes ONCASPAR Portfolio Acquisition, Aims to Broaden Patient Access to Leading Treatment for Leukemia
Jul 16, 2015 03:36 PM Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A
Jul 16, 2015 08:30 AM Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A
Jul 16, 2015 08:30 AM CORRECTING and REPLACING Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A
Jul 9, 2015 04:30 PM Baxalta to Host First Investor Conference Call on July 30, 2015
Jul 9, 2015 08:30 AM Baxalta Appoints Two New Directors to the Board, Further Diversifying With Strong Biopharmaceutical Leadership Experience
Jul 8, 2015 04:15 PM Baxter International Second Quarter 2015 Financial Results Conference Call
Jul 2, 2015 08:00 AM Baxter Announces Early Results of Debt Tender Offers
Jul 1, 2015 04:46 PM Baxter Announces Pricing of Debt Tender Offers
Jun 25, 2015 03:18 PM MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
Jun 25, 2015 07:00 AM U.S. FDA Grants Priority Review for MM-398 New Drug Application
Jun 24, 2015 09:00 AM Baxalta Reports Continued Progress on Phase 1/2 Clinical Trial of BAX335, Investigational Gene Therapy Treatment for Hemophilia B
Jun 22, 2015 06:30 AM Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
Jun 19, 2015 06:13 PM The Priceline Group Set to Join the S&P 100; Baxalta to Join the 500; Other Changes to S&P MidCap 400 & S&P SmallCap 600
Jun 19, 2015 09:00 AM Baxalta Demonstrates Commitment to Innovation in Hemophilia and Blood Disorders at ISTH 2015 Congress
Jun 19, 2015 08:00 AM Baxalta Announces Pricing of $5 Billion Private Placement Notes Offering
Jun 18, 2015 08:30 AM Baxter Announces Debt Tender Offers
Jun 12, 2015 03:30 AM Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis
Jun 11, 2015 05:00 PM Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer
Jun 10, 2015 09:00 AM Baxter’s Commitment to Innovative Programs and Advancing Its Sustainability Priorities Featured in Sixteenth Report
Jun 10, 2015 01:30 AM CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA
Jun 9, 2015 05:00 PM Baxter Announces Effectiveness of Baxalta Form 10 Registration Statement
Jun 5, 2015 04:30 PM Baxter’s Board of Directors Approves Separation of Baxalta and Declares Special Dividend of Baxalta Stock
Jun 1, 2015 04:12 PM Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
Jun 1, 2015 09:00 AM Baxter Ventures, Mayo Clinic and Velocity Pharmaceutical Development Announce the Formation of Vitesse Biologics, LLC, a Company Structured to Accelerate Therapeutic Innovation
Jun 1, 2015 09:00 AM Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation
May 31, 2015 11:20 PM PharmaEngine Announces Filing New Drug Application (NDA) of MM-398 (PEP02) to Taiwan FDA as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
May 30, 2015 07:30 AM Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
May 29, 2015 07:00 AM Baxter Presents Data Demonstrating Remote Technology May Help Reduce Barriers to Home Therapy
May 28, 2015 04:15 PM Baxter and Baxalta Executives to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
May 21, 2015 09:00 AM Baxter BioScience Files for European Approval of Investigational 20% Subcutaneous Immune Globulin Treatment for Primary Immunodeficiency
May 18, 2015 08:30 AM Baxter and Baxalta Highlight Business Strategies at Investor Conferences
May 15, 2015 05:26 PM Baxter Receives U.S. FDA Approval for 0.9% Sodium Chloride Injection, USP from Sabinanigo, Spain, Facility for the U.S. Market
May 13, 2015 09:00 AM Economists Anthony Culyer and Alan Maynard Named Co-Recipients of the 2015 William B. Graham Prize for Health Services Research
May 12, 2015 09:00 AM Baxter BioScience to Expand Global Oncology Footprint with Acquisition of Oncaspar® Portfolio for Leukemia
May 11, 2015 04:30 PM Baxter to Host May 2015 Investor Conferences
May 5, 2015 08:55 AM Baxter Declares Quarterly Dividend
May 4, 2015 10:00 AM PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients
Pages: 1 2 »» Last Page

Back to BAX Stock Lookup